Author:
Vaz Batista Marta,Pérez-García José Manuel,Garrigós Laia,García-Sáenz José Ángel,Cortez Patricia,Racca Fabricio,Blanch Salvador,Ruiz-Borrego Manuel,Fernández-Ortega Adela,Fernández-Abad María,Iranzo Vega,Gion María,Martrat Griselda,Alcalá-López Daniel,Pérez-Escuredo Jhudit,Sampayo-Cordero Miguel,Llombart-Cussac Antonio,Braga Sofia,Cortés Javier
Reference20 articles.
1. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan;Alder;NPJ Breast Cancer,2023
2. ENHERTU® (Fam-trastuzumab Deruxtecan-Nxki) [package Insert],2022
3. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial;Hurvitz;Lancet,2023
4. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial;André;Lancet,2023
5. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer;Modi;N. Engl. J. Med.,2020